Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases

被引:29
作者
Cesaro, S. [1 ]
Stenghele, C. [1 ]
Calore, E. [1 ]
Franchin, E. [2 ]
Cerbaro, I. [2 ]
Cusinato, R. [2 ]
Tridello, G. [1 ]
Manganelli, R. [2 ]
Carli, M. [1 ]
Palu, G. [2 ]
机构
[1] Univ Padua, Dept Pediat, I-35128 Padua, Italy
[2] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35128 Padua, Italy
关键词
paediatric malignancy; invasive aspergillosis; LightCycler PCR; galactomannan antigen;
D O I
10.1111/j.1439-0507.2008.01512.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
A reliable diagnosis of invasive aspergillosis (IA) is hampered by the difficulty in obtaining suitable tissue samples. To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the LightCycler PCR for the diagnosis of IA, 536 blood samples were collected over a 22-month period from 62 paediatric patients (median age 10 years, range 1-18) considered at risk of IA. The galactomannan antigen (GM) and fungal DNA were assessed on serial blood samples. IA was diagnosed in eight of 62 patients (13%): proven, five, probable, three. Sensitivity, specificity, PPV and NPV of LightCycler PCR varied according to the number of positive samples used to define positivity: 88%; 37%; 17% and 95% for single sample positivity; and 63%, 81%, 33% and 94% for serial sample positivity respectively. The concordance between positivity of LightCycler PCR assay and the diagnosis of IA was 79%. The single positivity of LightCycler PCR assay showed a good sensitivity for the diagnosis of IA in paediatric patients. The high NPV makes LightCycler PCR a promising tool in addition to GM testing to design a strategy of pre-emptive antifungal therapy, although further validation studies are needed.
引用
收藏
页码:497 / 504
页数:8
相关论文
共 37 条
[1]
Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies [J].
Adam, O ;
Aupérin, A ;
Wilquin, F ;
Bourhis, JH ;
Gachot, B ;
Chachaty, E .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (06) :917-920
[2]
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].
Ascioglu, S ;
Rex, JH ;
de Pauw, B ;
Bennett, JE ;
Bille, J ;
Crokaert, F ;
Denning, DW ;
Donnelly, JP ;
Edwards, JE ;
Erjavec, Z ;
Fiere, D ;
Lortholary, O ;
Maertens, J ;
Meis, JF ;
Patterson, TF ;
Ritter, J ;
Selleslag, D ;
Shah, PM ;
Stevens, DA ;
Walsh, TJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14
[3]
Prospective clinical evaluation of a LightCycler™-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients [J].
Buchheidt, D ;
Hummel, M ;
Schleiermacher, D ;
Spiess, B ;
Schwerdtfeger, R ;
Cornely, OA ;
Wilhelm, S ;
Reuter, S ;
Kern, W ;
Südhoff, T ;
Mörz, H ;
Hehlmann, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) :196-202
[4]
Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery [J].
Caillot, D ;
Casasnovas, O ;
Bernard, A ;
Couaillier, JF ;
Durand, C ;
Cuisenier, B ;
Solary, E ;
Piard, F ;
Petrella, T ;
Bonnin, A ;
Couillault, G ;
Dumas, M ;
Guy, H .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :139-147
[5]
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[6]
British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections [J].
Denning, DW ;
Kibbler, CC ;
Barnes, RA .
LANCET INFECTIOUS DISEASES, 2003, 3 (04) :230-240
[7]
Polymerase chain reaction for diagnosing invasive aspergillosis: Getting closer but still a ways to go [J].
Donnelly, JP .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (04) :487-489
[8]
Detection and identification of fungal pathogens in blood by using molecular probes [J].
Einsele, H ;
Hebart, H ;
Roller, G ;
Loffler, J ;
Rothenhofer, I ;
Muller, CA ;
Bowden, RA ;
vanBurik, JA ;
Engelhard, D ;
Kanz, L ;
Schumacher, U .
JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (06) :1353-1360
[9]
Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies:: Evidence from a meta-analysis of 3,597 patients [J].
Glasmacher, A ;
Prentice, A ;
Gorschlüter, M ;
Engelhart, S ;
Hahn, C ;
Djulbegovic, B ;
Schmidt-Wolf, IGH .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4615-4626
[10]
A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
GOODMAN, JL ;
WINSTON, DJ ;
GREENFIELD, RA ;
CHANDRASEKAR, PH ;
FOX, B ;
KAIZER, H ;
SHADDUCK, RK ;
SHEA, TC ;
STIFF, P ;
FRIEDMAN, DJ ;
POWDERLY, WG ;
SILBER, JL ;
HOROWITZ, H ;
LICHTIN, A ;
WOLFF, SN ;
MANGAN, KF ;
SILVER, SM ;
WEISDORF, D ;
HO, WG ;
GILBERT, G ;
BUELL, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) :845-851